ViiV Healthcare's Positive Action Europe Programme awards grants to 14 community-based organisations
Back grey arrow rt.gif
ViiV Healthcare's Positive Action Europe Programme awards grants to 14 community-based organisations
  Positive Action Europe fourth grant cycle comes to a close as 14 patient advocacy organisations across Europe have been awarded grants to deliver education, support services and care for people living with HIV.
London, Wednesday 14 June
- Today, ViiV Healthcare announce that 14 patient advocacy organisations will receivefunding as part of its Positive Action Europe Programme. After a thorough review of applications from across the region, the decision was made to award grants to 14 projects aimed to support people living with HIV in the community.
This year's programme attracted a total number of 78 applications - an increase in the number of applications received in 2016. The chosen applications were submitted by patient advocacy organisations from the Czech Republic, Romania, Macedonia, Malta, Poland, Spain, Serbia, UK, Ireland, Austria, Italy, Sweden, Slovakia and Cyprus.
As a testament to the strong impact of Positive Action Europe in previous years, ViiV Healthcare increased funding for this year's cycle. Since the start of the initiative in 2014, the programme has seen an increase of 150% in its overall funding with a total budget of GBP 250,000 available overall to the patient advocacy organisations.
"I am extremely proud to be involved in the Positive Action Europe programme. I have now been part of the Steering Committee for the last two grant cycles and seen how the programme has grown year on year. I've seen the real difference the programme makes to the lives of people living with HIV. Positive Action helps facilitate long-term change by supporting community based interventions which address the key challenges, such as stigma and retention in care. By empowering the HIV community to engage key stakeholders, the programme contributes to a better quality of life for those impacted by HIV." Damian Kelly, European AIDS Treatment Group.
"The Positive Action Programme is an immensely important initiative that supports organisations across Europe to promote testing and early diagnosis of HIV targeted at the key affected populations." Anna Lawson, Director, Global Strategic Initiatives UNAIDS 90-90-90.
For more information on the 14 patient advocacy organisations who received a grant in 2017, click here.
HIV in the EU
The HIV epidemic in Europe varies greatly across countries, and populations. The Positive Action Europe programme seeks to fund community-based projects that reach those most affected by HIV, particularly in marginalised or vulnerable populations. The programme uses a targeted approach to identify and respond to HIV-related issues at a local level, supporting projects that are specifically designed to tackle the drivers of HIV in local regions.
While Europe has made great strides in its response to the HIV epidemic, HIV in Europe remains a significant challenge to address:
⋅ There has been only an insignificant decline in the rate of new diagnoses over the last decade, from 6.6 per 100 000 population in 2006 to 6.3 per 100 000 in 2015.1
⋅ Men who have sex with men (MSM) account for 42% of all new HIV cases in Europe.1
⋅ There is growing evidence that migrant sub-groups are at greater risk of acquiring HIV after arrival in Europe. 1
⋅ Limited funding/budget has been meant that it is difficult to establish HIV prevention measures to reduce the number of new HIV infections.1
Multi-media links: PAE Video
- Ends -
Notes to editors
About ViiV Healthcare's Positive Action

Positive Action was created in 1992 as the first programme by a pharmaceutical company to support communities affected by HIV and AIDS. ViiV Healthcare is proud to continue the Positive Action programme and its valuable work with these communities. Positive Action works with those communities most vulnerable to HIV disease, including youth, girls and women, sex workers, gay men, men who have sex with men (MSM), transgender people, injecting drug users (IDU), the homeless and the incarcerated. Our projects range across education, prevention, care and treatment-related activity such as treatment literacy and community/clinical engagement. We also fund action research into how these areas can be improved.
For more information about Positive Action, please visit:
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please
Media enquiries:
Sebastien Desprez +44 (0) 20 8380 6275
Isabelle Scali +44 (0) 208 0474733
1) European Centre for Disease Prevention and Control. The status of the HIV response in the European Union/ European Economic Area, 2016. Stockholm. ECDC: 2017.

  iconpaperstack View Older Articles   Back to Top